Program
MONDAY 18th OCTOBER
8.00-8.40 - Registration Garvan Institute Galleria
8.40-8.45 - Welcome and Overview Garvan Institute Auditorium
Session 1 - Receptor-based signalling complexes - Sponsored by Novartis
8.45-9.10
Martin Lackmann – Monash University, Melbourne, Australia
INSIGHTS INTO MOLECULAR SWITCHES CONTROLLING EPH RTK FUNCTION
9.10-9.35
Michael Parker - St. Vincent’s Institute of Medical Research, Melbourne, Australia
ASSEMBLY OF THE GM-CSF RECEPTOR
9.35-10.00
Matthias Ernst - Ludwig Institute for Cancer Research, Melbourne, Australia
INTERLEUKIN-11, MORE THAN A SIDE-KICK IN LINKING INFLAMMATION TO GASTROINTESTINAL TUMOURIGENESIS
10.00-10.15
Thomas Garrett – Walter and Eliza Hall Institute of Medical Research, Parkville Australia
CRYSTAL STRUCTURE OF THE ENTIRE ECTODOMAIN OF GP130: INSIGHTS INTO THE MOLECULAR ASSEMBLY OF CYTOKINE RECEPTOR COMPLEXES
10.15-10.30
Peter Janes - Monash University, Melbourne, Australia
HETERO-OLIGOMERISATION OF EPH RECEPTORS AND EFFECTS ON TUMOUR CELL SIGNALLING AND BEHAVIOUR
10.30-11.00 - Coffee
Session 2 - Spatiotemporal regulation of signalling - Sponsored by Leica
11.00-11.40
Kjetil Taskén – University of Oslo, Norway
SPATIOTEMPORAL CONTROL OF CYCLIC AMP SIGNALING PROCESSES
11.40-12.05
Sandra Nicholson - Walter and Eliza Hall Institute of Medical Research Parkville Australia
THE SPRY DOMAIN-CONTAINING SOCS BOX PROTEINS SPSB1 and 2 TARGET INDUCIBLE NITRIC OXIDE SYNTHASE (iNOS) FOR UBIQUITINATION AND PROTEASOMAL DEGRADATION
12.05-12.30
Kirill Alexandrov - The University of Queensland, Brisbane
FRET-BIOSENSORS FOR CELLULAR HIGH-THROUGHPUT SCREENING OF SPECIFIC LIPID-MODIFICATION INHIBITORS
12.30-12.45
Patrick Humbert - Peter MacCallum Cancer Center, East Melbourne, Australia
A LARGE SCALE RNAI SCREEN IDENTIFIES AN EXTENSIVE NETWORK OF MAMMALIAN CELL POLARITY REGULATORS AS KEY MODIFIERS OF THE ONCOGENIC PROPERTIES OF RAS IN HUMAN CANCER
12.45-1.45 - Lunch (De Novo Cafeteria)
Session 3 - Signalling to tissue growth and metabolism - Sponsored by Millipore and Life Technologies
1.45-2.10
David James – Garvan Institute of Medical Research, Sydney, Australia
MAPPING THE INSULIN SIGNALLING NETWORK IN ADIPOCYTES
2.10-2.35
Kieran Harvey - Peter MacCallum Cancer Center, East Melbourne, Australia
CONTROL OF ORGAN SIZE AND REGENERATION BY THE HIPPO SIGNALLING PATHWAY
2.35-3.00
Jenny Gamble - Centenary Institute, Sydney, Australia
A NOVEL GENE, SENEX, REGULATES THE SENESCENCE/APOPTOSIS PHENOTYPE IN ENDOTHELIAL CELLS
3.00-3.25
Michael Waters - Institute for Molecular Bioscience, University of Queensland, Australia
GROWTH HORMONE RECEPTOR SIGNALLING
3.30-5.00 - Poster Session/Afternoon Tea (Garvan Institute Galleria)
Session 4 - Special Session Sponsored by the American Society for Biochemistry and Molecular Biology
5.00-5.40
John Scott – Howard Hughes Medical Institute, University of Washington, Seattle, USA
CELL SIGNALING IN SPACE AND TIME
5.40-5.55
Darren Saunders - Garvan Institute of Medical Research, Sydney, Australia
ILLUMINATING NOVEL UBIQUITIN AND UBL INTERACTORS USING HIGH-THROUGHPUT BIFC SCREENS
5.55-6.10
Jim Xuan - Lawson Heath Research Institute, University of Western Ontario, Canada
PROTO-ONCOGENIC ACTIVITY OF A NOVEL TRIM59 GENE, CHARACTERIZED IN MOUSE CANCER MODELS
6.10-6.50
Natalie Ahn - University of Colorado, USA
A NEW ROUTE TO CELL POLARITY THROUGH WNT5A SIGNALING
7.00-8.30 - Wine and cheese tasting (De Novo Cafeteria) - Sponsored by the Australian Proteome Analysis Facility
TUESDAY 19th OCTOBER
Session 5 - Haematopoietic cell signalling - Sponsored by Ozgene and Symansis
8.45-9.10
Robert Brink - Garvan Institute of Medical Research, Sydney, Australia
cIAP1/cIAP2 ACT VIA TRAF2 WITH DIFFERENTIAL INVOLVEMENT OF TRAF3 TO CONTROL IN VIVO B CELL SURVIVAL AND DIFFERENTIATION
9.10-9.35
Tony Tiganis - Monash University, Melbourne, Australia
TITLE TO BE ANNOUNCED
9.35-10.00
Wally Langdon – University of Western Australia, Crawley, Australia
MYELOID LEUKEMIA DEVELOPMENT IN C-CBL RING FINGER MUTANT MICE IS DEPENDENT ON FLT3 SIGNALLING
10.00-10.25
Mark Guthridge – Centre for Cancer Biology, South Australia Pathology, Australia
TARGETTING DEREGULATED CYTOKINE RECEPTOR SURVIVAL PATHWAYS IN ACUTE MYELOID LEUKEMIA
10.25-10.40
Evan Ingley - The University of Western Australia, Perth, Australia
CONTROLLING CELL SHAPE: THE LYN-LACM-NCK2/VAV2 PATHWAY
10.40-11.10 - Coffee
Session 6 - Lipid signalling - Sponsored by Cell Signaling Technology and Genesearch
11.10-11.35
Christina Mitchell - Monash University, Melbourne, Australia
THE PTDINS(3,4)P2 4-PHOSPHATASE, INPP4B, IS LOST IN HUMAN BASAL-LIKE BREAST CANCERS
11.35-12.00
Peter Shepherd - Dept of Molecular Medicine , The University of Auckland, New Zealand
ASSESSING THE ROLE OF CLASS-IA PI 3-KINASE ISOFORMS: IMPLICATIONS FOR THERAPEUTIC USE OF PI 3-KINASE INHIBITORS AS CANCER DRUGS
12.00-12.25
Trevor Biden - Garvan Institute of Medical Research, Sydney, Australia
SIGNALLING MECHANISMS OF LIPOTOXIC BETA CELL FAILURE IN TYPE 2 DIABETES
12.25-12.45
Xuxiao Zhang - Medical Research Council Laboratory of Molecular Biology, Cambridge UK
THE STRUCTURE OF A PHOSPHOINOSITIDE 3-KINASE β/p85 HETERODIMER ELUCIDATES THE MECHANISM OF ACTIVATION BY TYR-KINASE ASSOCIATED RECEPTORS
12.45-1.00
Wayne Phillips - Peter MacCallum Cancer Center, East Melbourne, Australia
EXPRESSION OF THE PI 3-KINASE MUTATION PIK3CAH1047R IN THE MOUSE MAMMARY GLAND INDUCES DUCTAL HYPERPLASIA AND TUMOURIGENESIS
1.00-2.00 - Lunch (De Novo Cafeteria)
Session 7 - Cancer cell signalling and targeted therapeutics - Sponsored by Cancer Institute NSW
2.00-2.40
Charles Sawyers - Howard Hughes Medical Institute, Memorial Sloan-Kettering Cancer Center, New York, USA
TITLE TO BE ANNOUNCED
2.40-3.05
Roger Daly - Garvan Institute of Medical Research, Sydney, Australia
CANCER PHENOTYPING BY PHOSPHOPROTEOMIC PROFILING
3.05-3.30
Andrew Scott – Ludwig Institute for Cancer Research, Melbourne, Australia
TITLE TO BE ANNOUNCED
3.30-3.45
Richard Pearson - Peter MacCallum Cancer Center, East Melbourne, Australia
GENOMIC PROFILING OF OVARIAN TUMOUR CELL LINES PROVIDES A PREDICTIVE SIGNATURE OF SENSITIVITY TO PF-4691502, A DUAL PI3-KINASE AND MTOR INHIBITOR
3.45-4.00
Alex Swarbrick - Garvan Institute of Medical Research, Sydney, Australia
HEDGEHOG LIGAND OVEREXPRESSION PREDICTS POOR OUTCOME IN BREAST CANCER AND IS A POTENTIAL THERAPEUTIC TARGET FOR METASTATIC DISEASE
4.00-4.30 - Afternoon tea
Session 8 - Special Session Sponsored by the American Society for Biochemistry and Molecular Biology
4.30-5.10
Art Weiss - Howard Hughes Medical Institute, University of California, San Francisco, USA
PROBING THE ROLE OF PROTEIN TYROSINE KINASES IN TCR SIGNALING WITH GENETICALLY-SELECTIVE INHIBITORS
5.10-5.25
Tilman Brummer - ZBSA and BIOSS, Albert-Ludwigs University, Freiburg, Germany
MODULATION OF BCR-ABL SIGNALLING BY THE GAB2 DOCKING PROTEIN
5.25-5.40
Cherlyn Ng - Institute of Molecular and Cell Biology, Proteos, Singapore
STRUCTURAL BASIS FOR A NOVEL INTRAPEPTIDYL H-BOND AND REVERSE BINDING OF c-Cbl-TKB SUBSTRATES
5.40-6.20
Tony Hunter - Molecular and Cell Biology Laboratory, The Salk Institute, California, USA
PROTEIN PHOSPHORYLATION IN CANCER AND THE DNA DAMAGE RESPONSE
6.20-6.30 - Closing remarks
